Dogwood Therapeutics, Inc. Interest Income (Expense), Nonoperating, Net
Dogwood Therapeutics, Inc. (DWTX) reported Interest Income (Expense), Nonoperating, Net of $66.35 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Income Statement › Other Income
us-gaap:InterestIncomeExpenseNonoperatingNet · last filed 2026-08-14
- Dogwood Therapeutics, Inc. interest income (expense), nonoperating, net for the quarter ending 2026-06-30 was $66.35K, a 40.43% decline year-over-year.
- Dogwood Therapeutics, Inc. interest income (expense), nonoperating, net for the quarter ending 2026-03-31 was $77.35K.
- Dogwood Therapeutics, Inc. interest income (expense), nonoperating, net for the quarter ending 2025-12-31 was $52.07K.
- Dogwood Therapeutics, Inc. interest income (expense), nonoperating, net for the quarter ending 2025-09-30 was $80.58K, a 293.31% increase year-over-year.
- Dogwood Therapeutics, Inc. interest income (expense), nonoperating, net for fiscal 2025 was $96.94K.
- Dogwood Therapeutics, Inc. interest income (expense), nonoperating, net for fiscal 2024 was -$92.19K, a 161.09% decline from fiscal 2023.
- Dogwood Therapeutics, Inc. interest income (expense), nonoperating, net for fiscal 2023 was $150.90K.
| Period end | Interest Income (Expense), Nonoperating, Net 3 month | Interest Income (Expense), Nonoperating, Net 6 month | Interest Income (Expense), Nonoperating, Net 9 month | Interest Income (Expense), Nonoperating, Net 12 month |
|---|---|---|---|---|
| 2026-06-30 | $66.35K 10-Q · filed 2026-08-14 | $143.70K 10-Q · filed 2026-08-14 | $195.77K derived: sum of 3 quarters · filed 2026-08-14 | $276.35K derived: sum of 4 quarters · filed 2026-08-14 |
| 2026-03-31 | $77.35K 10-Q · filed 2026-05-15 | $129.42K derived: sum of 2 quarters · filed 2026-05-15 | $210.00K derived: sum of 3 quarters · filed 2026-05-15 | $321.38K derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-12-31 | $52.07K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-18 | $132.65K derived: sum of 2 quarters · filed 2026-03-18 | $244.03K derived: sum of 3 quarters · filed 2026-08-14 | $96.94K 10-K · filed 2026-03-18 |
| 2025-09-30 | $80.58K 10-Q · filed 2025-11-07 | $191.96K derived: sum of 2 quarters · filed 2026-08-14 | $44.87K 10-Q · filed 2025-11-07 | -$110.57K derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-06-30 | $111.38K 10-Q · filed 2026-08-14 | -$35.71K 10-Q · filed 2026-08-14 | -$191.15K derived: sum of 3 quarters · filed 2026-08-14 | -$170.66K derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-03-31 | -$147.09K 10-Q · filed 2026-05-15 | -$302.53K derived: sum of 2 quarters · filed 2026-05-15 | -$282.04K derived: sum of 3 quarters · filed 2026-05-15 | -$262.05K derived: sum of 4 quarters · filed 2026-05-15 |
| 2024-12-31 | -$155.44K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-18 | -$134.95K derived: sum of 2 quarters · filed 2026-03-18 | -$114.96K derived: sum of 3 quarters · filed 2026-03-18 | -$92.19K 10-K · filed 2026-03-18 |
| 2024-09-30 | $20.49K 10-Q · filed 2025-11-07 | $40.48K derived: sum of 2 quarters · filed 2025-11-07 | $63.24K 10-Q · filed 2025-11-07 | $98.20K derived: sum of 4 quarters · filed 2025-11-07 |
| 2024-06-30 | $19.99K 10-Q · filed 2025-08-13 | $42.76K 10-Q · filed 2025-08-13 | $77.71K derived: sum of 3 quarters · filed 2025-08-13 | $116.92K derived: sum of 4 quarters · filed 2025-08-13 |
| 2024-03-31 | $22.77K 10-Q · filed 2025-05-09 | $57.72K derived: sum of 2 quarters · filed 2025-05-09 | $96.93K derived: sum of 3 quarters · filed 2025-05-09 | $133.25K derived: sum of 4 quarters · filed 2025-05-09 |
| 2023-12-31 | $34.95K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $74.17K derived: sum of 2 quarters · filed 2025-03-31 | $110.48K derived: sum of 3 quarters · filed 2025-03-31 | $150.90K 10-K · filed 2025-03-31 |
| 2023-09-30 | $39.22K 10-Q · filed 2024-11-08 | $75.53K derived: sum of 2 quarters · filed 2024-11-08 | $115.95K 10-Q · filed 2024-11-08 | |
| 2023-06-30 | $36.31K 10-Q · filed 2024-08-09 | $76.74K 10-Q · filed 2024-08-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 | |
| Xilio Therapeutics, Inc. (XLO) | United States | $0.052B | |
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| SCYNEXIS INC (SCYX) | United States | $0.045B | |
| Serina Therapeutics, Inc. (SER) | United States | $0.054B | -2.35 |
| Clene Inc. (CLNN) | United States | $0.054B | -1.99 |
| HERON THERAPEUTICS, INC. /DE/ (HRTX) | United States | $0.055B | -2.38 |